A Fifth COVID Vaccine Will Now Be Studied In The US

A nurse holds a vial of the COVID-19 vaccine at La Bonne Maison de Bouzanton care home in Mons, Belgium, Monday, Dec. 28, 2020. The vaccine, developed by BioNTech and Pfizer, was transported from a hospital in Leuven... A nurse holds a vial of the COVID-19 vaccine at La Bonne Maison de Bouzanton care home in Mons, Belgium, Monday, Dec. 28, 2020. The vaccine, developed by BioNTech and Pfizer, was transported from a hospital in Leuven to the residential care home on Monday, as Belgium begins its vaccination program starting with the most vulnerable. (AP Photo/Francisco Seco, Pool) MORE LESS
Start your day with TPM.
Sign up for the Morning Memo newsletter

WASHINGTON – A huge study of another COVID-19 vaccine candidate is getting underway Monday as states in the U.S. continue to roll out scarce supplies of the nation’s first shot options.

The U.S. has authorized emergency use of two vaccines, one made by Pfizer and BioNTech and the other by Moderna, but doses will be rationed for months.

The candidate made by Novavax Inc. is the fifth to reach final-stage testing in the U.S. Some 30,000 volunteers are needed to prove if this vaccine – a different kind than its Pfizer and Moderna competitors – really works and is safe.

“If you want to have enough vaccine to vaccinate all the people in the U.S. who you’d like to vaccinate – up to 85% or more of the population – you’re going to need more than two companies,” Dr. Anthony Fauci, the top U.S. infectious disease expert, told The Associated Press.

The study, which is funded by the U.S. government, is open to all adults but will focus on high-risk older adults and volunteers from Black and Hispanic communities who have been hard-hit by the virus. Two-thirds of volunteers will receive the vaccine and the rest will get dummy shots.

The Novavax candidate uses lab-grown harmless copies of the spike protein that coats the coronavirus to train the body to recognize if the real virus comes along. The Pfizer and Moderna vaccines instead use a newer technology, injecting the genetic code for that protein.

In the U.S., Johnson & Johnson and AstraZeneca also have vaccine candidates in late-stage U.S. testing.

Latest News

Notable Replies

  1. Avatar for tao tao says:

    This pandemic proved that the U.S. health care system is a disaster. Yes, we need to get vaccines out and bring the virus under control so that the economy can regenerate. There cannot be a prosperous economy without a healthy population. It’s time to follow through with the health care improvements most voters wanted. Without a health care infrastructure we will never be productive enough to keep up with the rest of the developed world.

  2. COVID19 is just the first in a series of new pathogens that are going to hit humans. If the US continues to react as with COVID19, we are in trouble at every level.

  3. Avatar for msm msm says:

    As the saying goes, “You’re only as strong as your weakest link.” and Trump is the weakest link just like Wilson was in the 1918 flu epidemic. Anderson Cooper had a good docu yesterday on CNN about the 1918 pandemic that showed the similarities between then and now. Leadership is important, and I think the medical community has stepped up, but the nation’s leadership is what is missing. Team work is important and Trump is not a team player.

  4. This is nice, but I want to know how the roll out is proceeding. Are the states finally getting the vaccine allotted or is it still being warehoused?

  5. I bought some Inovio stock when they were mentioned as a dark horse contender in the early days of the vaccine startups. I sold it when it made a decent run, and it fell back to approx. $10 a share. I heard there was some decently good news on their horizon…not all about Covid…and got back in again. Theirs, from what I can tell, does not require refrigeration but does need it’s own little delivery device to prick/inject.

    Does anyone here have any extra insight into their long-term chances of success, and if there will be enough room on the playing field for their unique approach?

Continue the discussion at forums.talkingpointsmemo.com

22 more replies

Participants

Avatar for discobot Avatar for ajm Avatar for richardinjax Avatar for msm Avatar for cervantes Avatar for becca656 Avatar for wanderer Avatar for horrido Avatar for callmeeric Avatar for ottnott Avatar for tao Avatar for ronbyers Avatar for zd123 Avatar for morrigan_2575 Avatar for castor_troy Avatar for libthinker Avatar for greenman66 Avatar for dicktater Avatar for rucleare

Continue Discussion
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Deputy Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: